Advances in targeted therapy for esophageal cancer.
Advances in targeted therapy for esophageal cancer.
复制标题
食管癌靶向治疗的进展。
DOI：
10.1038/s41392-020-00323-3
复制
发表时间：
2020-10-07
影响因子：
39.3
通讯作者：
Li B
中科院分区：
文献类型：
--
作者：
Yang YM;Hong P;Xu WW;He QY;Li B
食管癌是世界上致死率最高的恶性肿瘤之一，我国食管癌的发病率和死亡率均居前十位。目前，手术切除、放疗和化疗是食管癌的主要临床治疗手段。然而，由于常规治疗的有限疗效和严重不良反应，结果仍然不令人满意。靶向治疗作为一种新型的治疗手段，已被证实在食管癌的治疗中发挥着重要作用，其中包括分别针对表皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）的西妥昔单抗和贝伐单抗。此外，靶向表面抗原和信号通路或作用于免疫检查点的其他药物也在不断开发。例如，曲妥珠单抗，一种靶向人表皮生长因子受体2（HER-2）的单克隆抗体，已被美国食品药品监督管理局（FDA）批准作为HER-2阳性癌症的一线治疗药物。此外，PD-L1抑制剂pembrolizumab已被批准为PD-L1阳性或晚期食管鳞状细胞癌（ESCC）患者的高效药物。这些新型药物可单独使用或与其他治疗策略联合使用，以进一步改善癌症患者的治疗效果和预后。然而，不良反应，最佳剂量和有效的组合仍需要进一步研究。本文综述了食管癌靶向治疗的最新进展及相关药物的作用机制，并讨论了其有效性和安全性，为食管癌的精准医疗提供了临床依据。
Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy and chemotherapy are the primary clinical treatments for esophageal cancer. However, outcomes are still unsatisfactory due to the limited efficacy and severe adverse effects of conventional treatments. As a new type of approach, targeted therapies have been confirmed to play an important role in the treatment of esophageal cancer; these include cetuximab and bevacizumab, which target epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), respectively. In addition, other drugs targeting surface antigens and signaling pathways or acting on immune checkpoints have been continuously developed. For example, trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER-2), has been approved by the Food and Drug Administration (FDA) as a first-line treatment of HER-2-positive cancer. Moreover, the PD-L1 inhibitor pembrolizumab has been approved as a highly efficient drug for patients with PD-L1-positive or advanced esophageal squamous cell carcinoma (ESCC). These novel drugs can be used alone or in combination with other treatment strategies to further improve the treatment efficacy and prognosis of cancer patients. Nevertheless, adverse events, optimal dosages and effective combinations still need further investigation. In this review, we expound an outline of the latest advances in targeted therapies of esophageal cancer and the mechanisms of relevant drugs, discuss their efficacy and safety, and provide a clinical rationale for precision medicine in esophageal cancer.
登录
查看更多内容
DOI：
10.1097/pai.0000000000000243
发表时间：
2016-10
期刊：
Applied immunohistochemistry & molecular morphology : AIMM
影响因子：
--
作者：
Almhanna K;Rosa M;Henderson-Jackson E;Jiang K;Shamekh R;Sayegh Z;Malafa MP;Coppola D
通讯作者：
Coppola D
影响因子：
168.9
作者：
Fuchs, Charles S.;Tomasek, Jiri;Tabernero, Josep
通讯作者：
Tabernero, Josep
影响因子：
5.7
作者：
Franklin, Matthew C.;Navarro, Elizabeth C.;Kussie, Paul
通讯作者：
Kussie, Paul
影响因子：
82.9
作者：
通讯作者：
--
DOI：
10.1056/nejmoa1507643
发表时间：
2015-10-22
期刊：
The New England journal of medicine
影响因子：
--
作者：
Borghaei H;Paz-Ares L;Horn L;Spigel DR;Steins M;Ready NE;Chow LQ;Vokes EE;Felip E;Holgado E;Barlesi F;Kohlhäufl M;Arrieta O;Burgio MA;Fayette J;Lena H;Poddubskaya E;Gerber DE;Gettinger SN;Rudin CM;Rizvi N;Crinò L;Blumenschein GR Jr;Antonia SJ;Dorange C;Harbison CT;Graf Finckenstein F;Brahmer JR
通讯作者：
Brahmer JR